close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(OP:NUMIF)

0.0550 +0.0072 (+15.06%)
Streaming Delayed Price Updated: 3:55 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NUMIF

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Numinus Expands Research Capabilities with new Phoenix Clinical Research Site
The Phoenix Site is Numinus’ Third Research Facility in the US VANCOUVER, BC, Feb. 17, 2023 – Numinus Wellness Inc. (“Numinus”) (TSX:NUMI) (OTCQX:NUMIF), a mental health care company advancing... 
Via PressReach
Cybin, Compass Pathways Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 15, 2023
 
Via Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
 
Via Benzinga
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More 
Via Benzinga
Cybin, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Seelos Therapeutics, Cybin Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 8, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 7, 2023
 
Via Benzinga
Australia's Psychedelics Therapy Provides Hope For Treatment-Resistant Mental Health Conditions
As of July 1, psilocybin and MDMA (and related substances to both) can now be prescribed by authorized psychiatrists in Australia, which has become the 
Via Benzinga
Mind Medicine, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 3, 2023
 
Via Benzinga
'Sea Change': Irwin Naturals, Numinus And Field Trip Discuss Psychedelics At Cantor Webinar
Cantor Fitzgerald's Pablo Zuanic hosted a virtual panel discussion about the psychedelics industry with three ketamine therapy providers: Irwin Naturals (OTCMKTS: IWINF)’ CEO Klee Irwin, Field Trip H&W... 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 2, 2023
 
Via Benzinga
Psychedelic Stock Gainers And Losers From February 1, 2023
 
Via Benzinga
This Psychedelic-Assisted Therapy Study Offers Therapists Experience With Magic Mushroom Tea
Psychedelic-assisted therapy provider, Numinus Wellness Inc. 
Via Benzinga
GH Research, Mind Medicine Among Top Psychedelic Movers Of Today
 
Via Benzinga
Intelgenx Technologies, Cybin Among Top Psychedelic Movers Of Today
 
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 26, 2023
 
Via Benzinga
Biomind Labs, Intelgenx Technologies Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2023
 
Via Benzinga
Irwin Naturals, Numinus, Field Trip: Sector Analyst Compares Footprints, Cash, Organic Growth
The Analyst 
Via Benzinga
CEO Of Psychedelics Co. Numinus Expands On Q1 Financials Results: A Look At Revenue And Margin Growth
In our newest interview with Numinus Wellness Inc. (TSX:NUMI) (OTC: NUMIF), TDR Founder Shadd Dales spoke with CEO Payton Nyquvest in a conversation focused on first quarter 2023 financial results,... 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 23, 2023
 
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
Psychedelic Stock Gainers And Losers From January 19, 2023
 
Via Benzinga
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today